The Study of the Viability of Human Wharton's Jelly Mesenchymal Stem Cells in Alginate Capsules

Subject Areas : Journal of Animal Biology

Zahra Poursafavi ¹ ( Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran )
Saeed Abroun ² ( Department of Hematology, Faculty of Medical Sciences, Tarbiat Modarres University, Tehran, Iran )
Saeid Kaviani Jebeli ³ ( Department of Hematology, Faculty of Medical Sciences, Tarbiat Modarres University, Tehran, Iran )
Nasim Hayati Roudbari ⁴ ( Department of Hematology, Faculty of Medical Sciences, Tarbiat Modarres University, Tehran, Iran )

Received: 2022-04-26 Accepted : 2022-07-09 Published : 2023-02-20

Keywords: viability, Mesenchymal stem cells, Alginate, Wharton jelly,

Abstract :

Stem cells with high proliferative capacity can be isolated from different tissues of the body. These cells originate from the fetal mesoderm and are found in tissues such as bone marrow, fat tissue, amniotic fluid, and Wharton's jelly. In this study, the survival of Wharton's jelly human mesenchymal stem cells inside alginate capsules after 7, 14 and 21 days has been investigated. In this experimental study, 10 umbilical cord samples were obtained from pregnant mothers during caesarean section, and the vessels of the umbilical cord samples were isolated. Then it was cultured in DMEM-HG medium containing 10% FBS serum for 5 days. To show the stemness of these cells, CD73, CD34 and CD45 markers were evaluated by flow cytometry technique. After confirmation, the cells were encapsulated in alginate hydrogels. The viability of encapsulated cells was evaluated by trypan blue and MTT. The results showed that the capsules are spherical and have a uniform border and are homogeneously dispersed throughout the capsule. Wharton jelly encapsulation of mesenchymal stem cells did not change their morphology and viability. After 21 days, the survival of the encapsulated cells was maintained. Alginate as a three-dimensional biodegradable scaffold with suitable cell viability can be used as a suitable option for cell therapy and tissue engineering with the property of non-graft rejection.

References:

1- Abouelnaga H., El‑Khateeb D., Moemen Y., El‑Fert A., Elgazzar M., Khalil A. 2022. Characterization of mesenchymal stem cells isolated from Wharton’s jelly of the human umbilical cord. Egyptian Liver Journal, 12.1: 1-9.

2- Bajada S., Mazakova I., Richardson J., Ashammakhi., N. 2008. Updates on stem cells and their applications in regenerative medicine. Journal of Tissue Engineering and Regenerative Medicine, 2: 169-183.

3- Baksh D., Song L. 2004. Adult mesenchymal stem cells: characterization, differentiation, and application in cell and gene therapy. Journal of Cellular and Molecular Medicine 3:301-316

4- Beiki B.,  Zarrabi M., Radmanesh M. 2015. A rapid, simple and economical method for the isolationof mesenchymal stem cells from Wharton’s jellyby phosphate buffer saline. Scientific Journal of Iran Blood Transfus Organ, 12(2): 143-152.

5- Can A., Karahuseyinoglu S. 2007. Concise review: human umbilical cord stroma with regard to the source of fetus‐derived stem cells. Stem Cells, 25(11): 2886-2895

6- Carlin R., Davis D., Weiss M., Schultz B., Troyer D. 2006. Expression of early transcription factors Oct-4, Sox-2 and Nanog by porcine umbilical cord (PUC) matrix cells. Reproductive Biology and Endocrinology, 4(1): 1-13.

7-Charbord P. 2010. Bone marrow mesenchymal stem cells: historical overview and concepts. Human Gene Therapy, 21(9): 1045-1056.

8- Chayosumrit M., Tuch B., Sidhu K. 2010. Alginate microcapsule for propagation and directed differentiation of hESCs to definitive endoderm. Biomaterials, 31(3): 505-514.

9- Horwitz E., Andreef M., Frassoni F. 2006. Mesenchymal stromal cells. Current Opinion in Hematology, 13(6): 419.

10- Karahuseyinoglu S., Cinar O., Kilic E., Kara F., 2007. Biology of stem cells in human umbilical cord stroma: in situ and in vitro surveys. Stem Cells, 25(2): 319-331.

11 -Khalif F., Alwan A., Ralph P., Soliman S., Abdelrahim A., Abdelhafez E., Opara E. 2022. Effect of Alginate Microbead Encapsulation of Placental Mesenchymal Stem Cells on Their Immunomodulatory Function. Annals of Biomedical Engineering, 50: 291-302.

12- Rocca G.,  Anzalone R., Corrao S.,  Magno F., Loria T.,  Iacono M.,  Di Stefano A., Giannuzzi P.,  Marasà L., Cappello F., Zummo G., Farina F. 2009. Isolation and characterization of Oct-4+/HLA-G+ mesenchymal stem cells from human umbilical cord matrix: differentiation potential and detection of new markers. Histochemistry and Cell Biology, 131(2): 267-282.

13- Liao N., Su L., Cao Y., Qiu L., Xie R., Peng F., Cai P., Liu X., Song J., Zeng Y. 2022. Tracking Cell Viability for Adipose-Derived Mesenchymal Stem Cell-Based Therapy by Quantitative Fluorescence Imaging in the Second Near-Infrared Window. ACS nano, 13(7): 7791–7799.

14- Man Y., Wang P., Guoad Y., Xiang B.,Yang Y., PingGong Y., Dengc L. 2012. Angiogenic and osteogenic potential of platelet-rich plasma and adipose-derived stem cell laden alginate microspheres. Biomaterials, 33(34): 8802-8811.

15- Mcelreavey K., Irvine A., Ennis K.,  McLean W. 1991. Isolation, culture andcharacterisation of fibroblast-like cells derived from the Wharton's jelly portion of human umbilical cord. Biochemical Society Transactions,19(1): 29S

16- Mohseni Kouchesfehani H., Saraee F.,  Maleki M.,  Nikougoftar M.,  Khatami SM.,  Sagha M. 2014. Evaluation of surface markers and related genes of the human‎ umbilical cord derived Wharton’s jelly mesenchymal stem cells. Journal of Mazandaran University of Medical Sciences, 24(112): 24-32.

17- Mohseni Kouchesfahani H., Sanamiri K.H., Hashemitabar M. 2014. Application of Alginate Capsules as a Three Dimensional Scaffold for Differentiation of Wharton's Jelly Mesenchymal Stem Cells to Definitive Endoderm. Arak Medical University Journal (AMUJ) Original Article, 17(85): 54-66

18- Pereira W.C., Khushnoomama I., Madkaikar M., Ghosh M. 2008. Reproducible methodology for the isolation of mesenchymal stem cells from human umbilical cord and its potential for cardiomyocyte generation. Journal of Tissue Engineering and Regenerative Medicine, 2(7): 394-399.

19- Romanov Y., Svintsitskaya V. 2003. Searching for alternative sources of postnatal human mesenchymal stem cells: candidate MSC-like cells from umbilical cord. Stem Cells, 21(1): 105-110.

20- Said Y.,  El-Gamel N., Ali S. 2022. Evaluation of Human Wharton’s Jelly-Derived Mesenchymal Stem Cells Conditioning Medium (hWJ-MSCs-CM) or Scorpion Venom Breast Cancer Cell Line In Vitro. Journal of Gastrointestinal Cancer, 12: 1-14.

21- Sarugaser R., Lickorish D.,  Baksh D., Hosseini M., Davies J. 2005. Human umbilical cord perivascular (HUCPV) cells: a source of mesenchymal progenitors. Stem Cells 23(2): 220-229.

22-Troyer D., Weiss M. 2008. Concise review: Wharton's Jelly‐derived cells are a primitive stromal cell population. Stem Cells, 26(3): 591-599.

23-Valencic E.,  Piscianz E.,  Andolina M. 2010. The immunosuppressive effect of Wharton's jelly stromal cells depends on the timing of their licensing and on lymphocyte activation. Cytotherapy, 12(2): 154-160.

24- Wang H., Hung S., Peng S., Huang C., Wei H., Gou Y.  2004. Mesenchymal stem cells in the Wharton's jelly of the human umbilical cord. Stem Cells, 22(7): 1330-1337.

25- Wang X.Y., Lan Y., He W.Y., Zhang L. 2008. Identification of mesenchymal stem cells in aorta-gonad-mesonephros and yolk sac of human embryos. Blood, The Journal of the American Society of Hematology, 111(4): 2436-2443.

26. Wang N., Adams G., Buttery L., Falcone LH. 2009. Alginate encapsulation technology supports embryonic stem cells differentiation into insulin-producing cells. Journal of Biotechnology, 144(4): 304-312.

27- Weiss M., Anderson C., Medisetty S. 2008. Immune properties of human umbilical cord Wharton's jelly‐derived cells. Stem Cells, 26(11): 2865-2874.